Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) EBITDA (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed EBITDA for 6 consecutive years, with -$140.7 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 26.88% to -$140.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$274.5 million through Dec 2025, up 19.88% year-over-year, with the annual reading at -$274.5 million for FY2025, 19.88% up from the prior year.
  • EBITDA hit -$140.7 million in Q4 2025 for Lyell Immunopharma, down from -$38.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$6.0 million in Q4 2022 to a low of -$192.4 million in Q4 2024.
  • Historically, EBITDA has averaged -$64.3 million across 5 years, with a median of -$53.7 million in 2021.
  • Biggest five-year swings in EBITDA: skyrocketed 92.96% in 2022 and later tumbled 764.05% in 2023.
  • Year by year, EBITDA stood at -$85.3 million in 2021, then surged by 92.96% to -$6.0 million in 2022, then tumbled by 764.05% to -$51.8 million in 2023, then plummeted by 271.13% to -$192.4 million in 2024, then increased by 26.88% to -$140.7 million in 2025.
  • Business Quant data shows EBITDA for LYEL at -$140.7 million in Q4 2025, -$38.7 million in Q3 2025, and -$42.8 million in Q2 2025.